Rodent models of treatment-resistant depression
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Major depression is a prevalent and debilitating disorder and a substantial proportion of patients fail to reach remission following standard antidepressant pharmacological treatment. Limited efficacy with currently available antidepressant drugs highlights the need to develop more effective medications for treatment resistant patients and emphasizes the importance of developing better preclinical models that focus on treatment resistant populations. This review discusses methods to adapt and refine rodent behavioral models that are predictive of antidepressant efficacy to identify populations that show reduced responsiveness or are resistant to traditional antidepressants. Methods include separating antidepressant responders from non-responders, administering treatments that render animals resistant to traditional pharmacological treatments, and identifying genetic models that show antidepressant resistance. This review also examines pharmacological and non-pharmacological treatments regimes that have been effective in refractory patients and how some of these approaches have been used to validate animal models of treatment-resistant depression. The goals in developing rodent models of treatment-resistant depression are to understand the neurobiological mechanisms involved in antidepressant resistance and to develop valid models to test novel therapies that would be effective in patients that do not respond to traditional monoaminergic antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 20×
“Chronic fluoxetine produce antidepressant-like effect in subset of mice Not tested Samuels et al. (2011) Treatments that render rodents resistant to antidepressants Chronic adrenocorticotropic hormone (ACTH) Rats and mice administered chronic ACTH are insensitive to tricyclic antidepressants in the FST Yes (ECS, lithi…”
BackgroundInfluentialThe tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307 · cited 1×
“Repeated social defeat produces increased anhedonia, increased anxiety, and reduced social interaction and these behaviors present in a bimodal distribution of stress-susceptible and stress-resistant animals (Berton et al., 2006; Der-Avakian et al., 2014; Krishnan et al., 2007).”
BackgroundEssential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 2×
“Repeated social defeat produces increased anhedonia, increased anxiety, and reduced social interaction and these behaviors present in a bimodal distribution of stress-susceptible and stress-resistant animals (Berton et al., 2006; Der-Avakian et al., 2014; Krishnan et al., 2007).”
BackgroundThe mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“…conditional (cortex and hippocampus) knockout mice Attenuated antidepressant response to desipramine in the FST No, ketamine inactive in FST Autry et al. (2011), Monteggia et al. (2004), Monteggia et al. (2007) Regulator of G protein Signaling 4 (RGS4) constitutive and nucleus accumbens…”
BackgroundWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 2×
“Chronic behavioral models include novelty-suppressed feeding (Bodnoff et al., 1988), novelty-induced hypophagia (Dulawa and Hen, 2005), olfactory bulbectomy (Breuer et al., 2007), chronic mild stress (Willner, 1997, 2005), and chronic social defeat stress (Berton et al., 2006).”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735 · cited 1×
“Introduction Major depressive disorder is a considerable public health problem affecting approximately 16% of adults in the United States (Kessler et al., 2003) and is the fourth leading cause of disease burden worldwide (Ustun et al., 2004).”
BackgroundWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 2×
“Chronic behavioral models include novelty-suppressed feeding (Bodnoff et al., 1988), novelty-induced hypophagia (Dulawa and Hen, 2005), olfactory bulbectomy (Breuer et al., 2007), chronic mild stress (Willner, 1997, 2005), and chronic social defeat stress (Berton et al., 2006).”
BackgroundThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“A hypodopaminergic state is thought to produce anhedonia and drugs that increase dopaminergic activity in the mesolimbic dopamine system may reverse the anhedonia associated with depression (Dunlop and Nemeroff, 2007; Nestler and Carlezon, 2006).”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“A recent active placebo controlled trial demonstrated fast-acting, but transient effects of ketamine in treatment-resistant depression patients (Murrough et al., 2013).”
BackgroundA cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865 · cited 1×
“Deep brain stimulation in brain regions such as the subcallosal cingulate gyrus (Lozano et al., 2012; Mayberg et al., 2005) and ventral striatum/nucleus accumbens (Bewernick et al., 2010; Bewernick et al., 2012) offer promise for treatment in antidepressant resistant populations.”
BackgroundSaarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789
Essential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685 · cited 2×
“…(cortex and hippocampus) knockout mice Attenuated antidepressant response to desipramine in the FST No, ketamine inactive in FST Autry et al. (2011), Monteggia et al. (2004), Monteggia et al. (2007) Regulator of G protein Signaling 4 (RGS4) constitutive and nucleus accumbens knockout Reduced…”
BackgroundEffects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671
Cryan, J. F., & Mombereau, C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001457 · Cited by 616 · cited 1×
“…that render rodents resistant to antidepressants (e.g. adrenocorticotropic hormone Kitamura et al., 2002 or inflammation Sukoff Rizzo et al., 2012); (3) Genetic models that show resistance to traditional antidepressant treatment (e.g. use of genetically modified mice Cryan and Mombereau, 2004).”
BackgroundA Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580 · cited 1×
“Treatment-resistant depression has been estimated to present an annual added societal cost $29–$48 billion, making the total societal costs of major depression in the United States $106–$118 billion per year (Mrazek et al., 2014).”
BackgroundAlterations in 5-HT 1B Receptor Function by p11 in Depression-Like States
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., Yacoubi, M. E., Vaugeois, J.-M., Nomikos, G. G., & Greengard, P. (2006) · Science · doi:10.1126/science.1117571 · Cited by 572 · cited 30×
“In addition, C57BL/6JRj mice were responsive to both paroxetine and citalopram in the TST (Ripoll et al., 2003).”
BackgroundInfluentialMonteggia, L. M., Luikart, B., Barrot, M., Theobold, D., Malkovska, I., Nef, S., Parada, L. F., & Nestler, E. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.021 · Cited by 502 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript BDNF conditional knockouts, with loss of BDNF restricted to the hippocampus and cortex, showed no response to desipramine in the FST (Monteggia et al, 2004, 2007).”
BackgroundReview and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript response (Kato and Serretti, 2010).”
BackgroundMcMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448 · cited 1×
“In addition, the stress-susceptible rats with the highest intracranial self-stimulation thresholds showed the poorest antidepressant outcome, similar to clinical populations in which more severe anhedonia is a predictor of poorer antidepressant response (McMakin et al., 2012).”
BackgroundThe effects of chronic antidepressant treatment in an animal model of anxiety
Bodnoff, S., Suranyi-Cadotte, B., Aitken, D., Quirion, R., & Meaney, M. (1988) · Psychopharmacology · doi:10.1007/bf00181937 · Cited by 437 · cited 1×
“Chronic behavioral models include novelty-suppressed feeding (Bodnoff et al., 1988), novelty-induced hypophagia (Dulawa and Hen, 2005), olfactory bulbectomy (Breuer et al., 2007), chronic mild stress (Willner, 1997, 2005), and chronic social defeat stress (Berton et al., 2006).”
BackgroundWalker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 1×
“Clinical support for this hypothesis comes from studies showing that the muscarinic antagonist scopolamine produced rapid antidepressant responses in depressed patients (Drevets and Furey, 2010; Furey and Drevets, 2006) as well as treatment-resistant patients (Ellis et al., 2014).”
ResultAdachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.019 · Cited by 380
Bewernick, B. H., Kayser, S., Sturm, V., & Schlaepfer, T. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.44 · Cited by 371 · cited 1×
“Deep brain stimulation in brain regions such as the subcallosal cingulate gyrus (Lozano et al., 2012; Mayberg et al., 2005) and ventral striatum/nucleus accumbens (Bewernick et al., 2010; Bewernick et al., 2012) offer promise for treatment in antidepressant resistant populations.”
BackgroundLozano, A. M., Giacobbe, P., Hamani, C., Rizvi, S. J., Kennedy, S. H., Kolivakis, T. T., Debonnel, G., Sadikot, A. F., Lam, R. W., Howard, A. K., et al. (2012) · Journal of Neurosurgery · doi:10.3171/2011.10.jns102122 · Cited by 356
O’Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., & Dinan, T. G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.013 · Cited by 355
Nicotinic receptors in the brain. Links between molecular biology and behavior
Picciotto, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00146-3 · Cited by 354 · cited 1×
“(α7 receptors are also widely distributed with high levels in the cortex and hippocampus (see Picciotto et al., 2000).”
BackgroundBoldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J., Mann, J. J., & Arango, V. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.024 · Cited by 348
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · cited 1×
“For example, one study found that patients who still showed elevated cortisol in response to the dexamethasone/ corticotropin-releasing hormone test after 2–3 weeks of antidepressant treatment showed poor clinical outcome at 5 weeks (Ising et al., 2007).”
BackgroundCelada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323 · cited 1×
“As the 5-HT1A autoreceptors desensitize following chronic antidepressant treatment, the inhibition is removed allowing greater activation of postsynaptic serotonin receptors (Celada et al., 2013).”
BackgroundAntidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285 · cited 1×
“Ketamine’s antidepressant properties have been demonstrated in several animal models of antidepressant efficacy (reviewed in Browne and Lucki, 2013) as well as in some treatmentresistant depression models.”
BackgroundNicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Isingrini, E., Camus, V., Le Guisquet, A.-M., Pingaud, M., Devers, S., & Belzung, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010404 · Cited by 277 · cited 2×
“Fluoxetine reversed the depressive-like behaviors in mice fed the normal diet but had no effect on mice fed the high fat diet (Isingrini et al., 2010).”
BackgroundSukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & Brandon, N. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.120 · Cited by 241
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 1×
“Clinical support for this hypothesis comes from studies showing that the muscarinic antagonist scopolamine produced rapid antidepressant responses in depressed patients (Drevets and Furey, 2010; Furey and Drevets, 2006) as well as treatment-resistant patients (Ellis et al., 2014).”
ResultIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript subunit of the NMDA receptor such as MK-0657 (Ibrahim et al., 2012) and CP-101,606 (Preskorn et al., 2008) have shown promising results in treating treatment resistant depression patients.”
BackgroundCarvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior
Warner-Schmidt, J. L., Schmidt, E. F., Marshall, J. J., Rubin, A. J., Arango-Lievano, M., Kaplitt, M. G., Ibañez-Tallon, I., Heintz, N., & Greengard, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209293109 · Cited by 163 · cited 28×
“In addition, C57BL/6JRj mice were responsive to both paroxetine and citalopram in the TST (Ripoll et al., 2003).”
BackgroundInfluentialCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123 · cited 1×
“Overall, findings on augmentation with atypical antipsychotics have been positive (Carvalho et al, 2014; Kato and Chang, 2013).”
BackgroundCaldarone, B. J., Harrist, A., Cleary, M. A., Beech, R. D., King, S. L., & Picciotto, M. R. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.010 · Cited by 122
Self-citationBelzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106 · cited 2×
“…action (e.g. neurokinin (NK) receptor NK1, NK2, NK3 antagonists, corticotrophin releasing factor receptor 1 (CRF1) antagonists, vasopressin receptor 1b (V1b) antagonists) showed promise in traditional animal antidepressant models but failed to show consistent efficacy in the clinic (Belzung, 2014).”
BackgroundSomatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS
Cusin, C., & Dougherty, D. D. (2012) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-2-14 · Cited by 98
Neurogenic Effects of Fluoxetine Are Attenuated in p11 (S100A10) Knockout Mice
Egeland, M., Warner-Schmidt, J., Greengard, P., & Svenningsson, P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.024 · Cited by 94
Gene–Environment Interaction in Major Depression and Antidepressant Treatment Response
Keers, R., & Uher, R. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-011-0251-x · Cited by 94
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90 · cited 1×
“Therefore, much focus has been placed on examining the neurobiology of serotonergic systems as a mechanism of treatmentresistant depression (Coplan et al., 2014).”
BackgroundPharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test
Crowley, J. J., Brodkin, E. S., Blendy, J. A., Berrettini, W. H., & Lucki, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301065 · Cited by 61 · cited 27×
“In addition, C57BL/6JRj mice were responsive to both paroxetine and citalopram in the TST (Ripoll et al., 2003).”
BackgroundInfluentialTowards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
Caldarone, B. J., Wang, D., Paterson, N. E., Manzano, M., Fedolak, A., Cavino, K., Kwan, M., Hanania, T., Chellappan, S. K., Kozikowski, A. P., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2271-y · Cited by 47
Self-citationVieta, E., Thase, M. E., Naber, D., D’Souza, B., Rancans, E., Lepola, U., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.008 · Cited by 43 · cited 1×
“…anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript dexmecamylamine (TC-5214) showed promise in early clinical trials as an effective add-on to traditional antidepressants in treatment-resistant patients, but failed to show efficacy in a large Phase III trial (Vieta et al., 2014).”
BackgroundThe β4 nicotinic receptor subunit modulates the chronic antidepressant effect mediated by bupropion
Radhakrishnan, R., Santamaría, A., Escobar, L., & Arias, H. R. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.08.009 · Cited by 12
Cited by
Antoniuk, S., Bijata, M., Ponimaskin, E., & Wlodarczyk, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.002 · Cited by 750
Animal models of major depression: drawbacks and challenges
Planchez, B., Surget, A., & Belzung, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02084-y · Cited by 480
Dendritic Spines in Depression: What We Learned from Animal Models
Qiao, H., Li, M.-X., Xu, C., Chen, H.-B., An, S.-C., & Ma, X.-M. (2016) · Neural Plasticity · doi:10.1155/2016/8056370 · Cited by 446
Reinforcement learning in depression: a review of computational research
Chen, C., Takahashi, T., Nakagawa, S., Inoue, T., & Kusumi, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.005 · Cited by 233
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
Metadata
- Authors
- Caldarone, B. J., Zachariou, V., & King, S. L.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 753
- Pages
- 51-65
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W1982818125
- Cited by
- 50
- References
- 56
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.